case_images: PMC9315103_01
case_images: Treatment timeline. CR, complete response; PR, partial response; SD stable disease; PD, progression disease; BEP, bleomycin, etoposide, and cisplatin.
case_images: fonc-12-916790-g001.jpg
case_images: PMC9315103_01_fonc-12-916790-g001.jpg
case_images: f1
case_images: The treatment timeline is shown in  Figure 1 . The patient had undergone debulking surgery for FIGO stage IA
case_images: Radiological imaging of the patient before and after the combination treatment of camrelizumab and apatinib. (A)
  18F-FDG positron emission tomography (PET)/CT performed on October 23, 2019, showing recurrence before treatment (baseline). (B, C) PET/CT performed on October 9, 2020 (B) and November 16, 2021 (C) showing the reduced tumor size and SUVmax at 12 months and 25 months after the initiation of treatment, respectively. The red circle indicates the tumor.
case_images: fonc-12-916790-g002.jpg
case_images: PMC9315103_01_fonc-12-916790-g002.jpg
case_images: f2
case_images: A follow-up 18F-FDG positron emission tomography (PET)/CT imaging indicated enlarged retroperitoneal lymph nodes measuring 3.9 x 3.7 cm on October 23, 2019 ( Figure 2A ). Follow-up PET/CT scans at 12 months ( Figure 2B ) and 25 months ( Figure 2C ) after the initiation of treatment demonstrated a sustained disease remission, with the tumor size of 2.7 x 2.4 cm and 2.7 x 1.9 cm, respectively.